AI Article Synopsis
- The study assessed the effects of a nanodispersion (CgND) on blood sugar levels, antioxidant capacity, and enzyme inhibition, alongside its safety profile.
- CgND showed comparable hypoglycemic effects to the drug glibenclamide in diabetic mice and demonstrated significant inhibition of α-glucosidase and lipase enzymes.
- The nanodispersion remained stable over a year, exhibited strong antioxidant activity, and was found to be non-cytotoxic, suggesting its potential for treating Type II diabetes and obesity-related issues.
Article Abstract
Purpose: This study aimed to evaluate the hypoglycemic effect, antioxidant, α-glucosidase and lipase inhibitory activity, and the cytotoxicity of the nanodispersion (CgND).
Methods: The hypoglycemic effect was evaluated in alloxan-induced diabetic mice. The particle size, polydispersion index, ζ-potential, and conductivity, as well as the drug-loaded content, were monitored in shelf-live, along a year. The delivery profile was evaluated in simulated intestinal fluids at pH 6.5 and 7.4. The antioxidant effect was evaluated as DPPH and ABTS inhibition. The murine α-glucosidase inhibitory activity and the lipase-inhibitory effect were evaluated Cytotoxicity was evaluated by the Alamar blue test.
Results: CgND remained stable for a year in shelf conditions. The hypoglycemic effect in a dose of 10 mg/kg was not statistically different from glibenclamide 25 mg/kg. Nanoparticles released 100% of extract in 120 min at pH 6.5 and 7.4. Nanodispersion exhibited a potent α-glucosidase and lipase-inhibitory effect with IC of 3.96 and 0.58 µg/mL, respectively. A strong antioxidant activity against DPPH (IC 0.65 µg/mL) and ABTS (0.48 µg/mL) was also observed. The hypoglycemic effect could occur, at least in part, via antioxidant and α-glucosidase inhibition. CgND is non-cytotoxic in MRC-5 line cell. This nanodispersion is a promising nanotechnological product that could be used in pharmaceuticals for the treatment of Type II diabetes and related complications as obesity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362179 | PMC |
| http://dx.doi.org/10.1016/j.jsps.2018.10.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TITAL: targeting renal fibrosis with sulforaphane-a promising therapeutic strategy.
Int Urol Nephrol
December 2024
Nishtar Medical University, Multan, Pakistan.
Renal fibrosis is a hallmark of chronic kidney disease, characterized by the excessive accumulation of extracellular matrix proteins. Sulforaphane, a potent antioxidant found in cruciferous vegetables, has shown promise in targeting renal fibrosis. By inhibiting fibrotic pathways, such as TGF-β signaling, and promoting antioxidant defenses, sulforaphane may offer a novel therapeutic strategy for mitigating kidney damage and slowing disease progression.
View Article and Find Full Text PDFCetyltrimethylammonium Chloride (CTAC) and Its Formulated Mouthwash Reduce the Infectivity of Streptococcus mutans and Candida albicans in Mono and Dual State.
Appl Biochem Biotechnol
December 2024
Department of Biotechnology, Science Campus, Alagappa University, Karaikudi, India.
Early childhood caries (ECC), a severe form of dental caries, is exacerbated by the synergistic interaction between Streptococcus mutans and Candida albicans, leading to greater disease severity than their individual effects. This underscores the need for more targeted and potent therapeutic alternatives. Given the promising anti-infective properties of quaternary ammonium surfactants (QAS), this study explores the microbicidal properties of one such QAS, cetyltrimethylammonium chloride (CTAC), against both individual- and dual-species cultures of S.
View Article and Find Full Text PDFStrategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras.
ACS Nano
December 2024
Faculty of Materials Science, Shenzhen MSU-BIT University, Shenzhen 518100, P. R. China.
Protein hydrolysis targeted chimeras (PROTACs) represent a different therapeutic approach, particularly relevant for overcoming challenges associated with traditional small molecule inhibitors. These challenges include targeting difficult proteins that are often deemed "undruggable" and addressing issues of acquired resistance. PROTACs employ the body's own E3 ubiquitin ligases to induce the degradation of specific proteins of interest (POIs) through the ubiquitin-proteasome pathway.
View Article and Find Full Text PDFpH-Ultrasensitive Membranolytic Polyesters with Alternating Sequence of Ionizable and Hydrophobic Groups for Selective Oncolytic Therapy.
J Am Chem Soc
December 2024
School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China.
Oncolytic therapy, inducing cell death via cell membrane lysis, holds considerable promise in cancer treatment. However, achieving precise control over the structure and function of oncolytic materials for highly selective oncolytic therapy is a key challenge in the context of the subtle differences between tumor and normal tissues/cells. Herein, we report the development of pH-ultrasensitive oncolytic polyesters (pOPs) with an alternating sequence of ionizable and hydrophobic groups.
View Article and Find Full Text PDFDiscovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.
J Am Chem Soc
December 2024
Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States.
Discovery of cancer immunogenic chemotherapeutics represents an emerging, highly promising direction for cancer treatment that uses a chemical drug to achieve the efficacy of both chemotherapy and immunotherapy. Herein, we report a high-throughput screening platform and the subsequent discovery of a new class of cancer immunogenic chemotherapeutic leads. Our platform integrates informatics-based activity metabolomics for the rapid identification of microbial natural products with both novel structures and potent activities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!